-
1Academic Journal
المؤلفون: I. M. Shevchuk, N. D. Movchan, И. М. Шевчук, Н. Д. Мовчан
المصدر: Cancer Urology; Том 19, № 4 (2023); 44-51 ; Онкоурология; Том 19, № 4 (2023); 44-51 ; 1996-1812 ; 1726-9776
مصطلحات موضوعية: акситиниб, Pembroria®, biosimilar, metastatic renal cell carcinoma, lenvatinib, axitinib, Пемброриа®, биосимиляр, метастатический почечно-клеточный рак, ленватиниб
وصف الملف: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1787/1504; Рак паренхимы почки. Клинические рекомендации 2023 г. Доступно по: https://oncology-association.ru/wp-content/uploads/2023/11/rak-pochki_23.pdf.; Powles T., Albiges L., Bex A. et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 2021;32(12):1511–9. DOI:10.1016/j.annonc.2021.09.014; Motzer R., Jonasch E., Agarwal N. et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20(1):71–90. DOI:10.6004/jnccn.2022.0001; Ljungberg B., Albiges L., Abu-Ghanem Y. et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol 2019;75(5):799–810. DOI:10.1016/j.eururo.2019.02.011; Powles T., Plimack E.R., Soulières D. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol 2020;21(12):e553]. Lancet Oncol 2020;21(12):1563–73. DOI:10.1016/S1470-2045(20)30436-8; Motzer R.J., Porta C., Eto M. et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). J Clin Oncol 2021;39(suppl 6):269. DOI:10.1200/JCO.2021.39.6_suppl.269; Инструкция по применению медицинского препарата Пемброриа. Доступно по: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b50afaa4-67c8-4d9c-9392-366a3322a7ec.; Eisenhauer E.A., Therasse P., Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. DOI:10.1016/j.ejca.2008.10.026; Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794–9. DOI:10.1200/JCO.2008.21.4809; Grünwald V. Poster presented at the ASCO Annual Meeting; 04–08 June, 2021; Virtual Format; abstract #4560. J Clin Oncol 2021;39:15_suppl:4560.; Rini B., Plimack E., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol 2023;41(suppl 17):abstr LBA4501. DOI:10.1200/JCO.2023.41.17_suppl.LBA450; Motzer R., Porta C., Alekseev B. et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol 2022;23(6):768–80. DOI:10.1016/S1470-2045(22)00212-1; https://oncourology.abvpress.ru/oncur/article/view/1787
-
2Academic Journal
المؤلفون: Yu. V. Alymov, I. S. Romanov, A. V. Ignatova, Ю. В. Алымов, И. С. Романов, А. В. Игнатова
المساهمون: The publication was prepared with the sponsorship of BIOCAD., Публикация подготовлена при спонсорской поддержке компании BIOCAD.
المصدر: Head and Neck Tumors (HNT); Том 13, № 2 (2023); 35-43 ; Опухоли головы и шеи; Том 13, № 2 (2023); 35-43 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2023-13-2
مصطلحات موضوعية: плоскоклеточный рак, drug treatment, pembrolizumab, pembroria, carcinoma, head and neck, squamous cell carcinoma, лекарственное лечение, пембролизумаб, пемброриа, карцинома, голова и шея
وصف الملف: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/887/584; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018; El-Naggar A.K., Chan J.K.C., Grandis J.R., Slootweg P.J. WHO classification of head and neck tumours. 2017. Available at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Head-And-Neck-Tumours-2017; Sanderson R.J., Ironside J.A. Squamous cell carcinomas of the head and neck. BMJ 2002;325(7368):822–7. DOI:10.1136/bmj.325.7368.822; Pignon J.P., le Maître A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(91):4–14. DOI:10.1016/j.radonc.2009.04.014; Bernier J., Domenge C., Ozsahin M. et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–52. DOI:10.1056/NEJMoa032641; Cooper J.S., Pajak T.F., Forastiere A.A. et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350(19):1937–44. DOI:10.1056/NEJMoa032646; Reeves T.D., Hill E.G., Armeson K.E., Gillespie M.B. Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data. Otolaryngol Head Neck Surg 2011;144(5):676–84. DOI:10.1177/0194599811399559; Jacobs C., Lyman G., Velez-García E. et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–63. DOI:10.1200/JCO.19; Grau J.J., Caballero M. et al. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol 2009;129(11):1294–9. DOI:10.3109/00016480802590451; Catimel G., Verweij J., Mattijssen V. et al. Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5(6):533–7. DOI:10.1093/oxfordjournals.annonc.a058908; Guardiola E., Peyrade F., Chaigneau L. et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 2004;40(14):2071–6. DOI:10.1016/j.ejca.2004.05.019; Martinez-Trufero J., Isla D., Adansa J.C. et al. Phase II study of capecita-bine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102(12):1687–91. DOI:10.1038/sj.bjc.6605697; Guntinas-Lichius O., Appenrodt S., Veelken F., Krug B. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 2006;116(4):613–8. DOI:10.1097/01.mlg.0000208366.34683.58; Gibson M.K., Li Y., Murphy B. et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562–7. DOI:10.1200/JCO.2005.01.057; Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116–27. DOI:10.1056/NEJMoa0802656; Grandis J., Tweardy D. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579–84.; Baselga J., Trigo J.M., Bourhis J. et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5568–77. DOI:10.1200/JCO.2005.07.119; Herbst R.S., Arquette M., Shin D.M. et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(24):5578–87. DOI:10.1200/JCO.2005.07.120; Vermorken J.B., Trigo J., Hitt R. et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171–7. DOI:10.1200/JCO.2006.06.7447; León X., Hitt R., Constenla M. et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005;17(6):418–24. DOI:10.1016/j.clon.2005.02.014; Guigay J., Fayette J., Mesia R. et al. TPExtreme randomized trial: TPEx versus extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(15):6002.; Badoual C., Hans S., Merillon N. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013;73(1):128–38. DOI:10.1158/0008-5472.CAN-12-2606; Zandberg D.P., Strome S.E. The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol 2014;50:627–32. DOI:10.1016/j.oraloncology.2014.04.003; Cohen E.E.W., Soulières D., Le Tourneau C. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. DOI:10.1016/S0140-6736(18)31999-8; Harrington K.J., Soulières D., Le Tourneau C. et al. Quality of Life with pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma: KEYNOTE-040. J Natl Cancer Inst 2021;113(2):171–81. DOI:10.1093/jnci/djaa063; Soulieres D., Harrington K.J., Le Tourneau C. et al. 658MO Pembro lizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. Ann Oncol 2022; 33(7):S843.; Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;23;394(10212):1915–28. DOI:10.1016/S0140-6736(19)32591-7; Rischin D., Harrington K.J., Greil R. et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(Suppl. 15):6000. DOI:10.1200/JCO.2019.37.15_suppl.6000; Harrington K.J., Burtness B., Greil R. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol 2023;41(4):790–802. DOI:10.1200/JCO.21.02508; Tahara M., Greil R., Rischin D. et al. 659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048. Ann Oncol 2022;33(Suppl. 7): S295–322. DOI:10.1016/annonc/annonc1056; Chen W.C., Chu P.Y., Lee Y.T. et al. Pembrolizumab for recurrent/ metastatic head and neck squamous cell carcinoma in an Asian population. Medicine (Baltimore) 2017;96(52):e9519. DOI:10.1097/MD.0000000000009519; He Y., Zeng J., Wei Z. et al. Comparison of second-line treatments for patients with platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and bayesian network meta-analysis. Cancers (Basel) 2022;14(18):4472. DOI:10.3390/cancers14184472; Wagner S.M., Magnes T., Melchardt T. et al. Real-world data of palliative first-line checkpoint inhibitor therapy for head and neck cancer. Anticancer Res 2023;43(3):1273–82. DOI:10.21873/anticanres.16274; Sano D., Tokuhisa M., Takahashi H. et al. Real-world therapeutic outcomes of the pembrolizumab regimen as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck: a single-center retrospective cohort study in Japan. Anticancer Res 2022;42(9):4477–84. DOI:10.21873/anticanres.15948; Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В. и др. Практические рекомендации по лечению злокачественных опухолей головы и шеи. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2022;12:94–112.; https://ogsh.abvpress.ru/jour/article/view/887
-
3Academic Journal
المؤلفون: Алымов Ю.В., Романов И.С., Игнатова А.В.
المصدر: Опухоли головы и шеи